Accessibility Menu
Avadel Pharmaceuticals Plc logo

Avadel Pharmaceuticals Plc

(NASDAQ) AVDL

This security has been delisted. This page is retained for historical reference.

Avadel Pharmaceuticals Plc last closing stock price
MetricPriceDate
Last closeUSD 21.642026-02-12
Avadel Pharmaceuticals Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.19%USD 21.602026-02-05
1 month+0.74%USD 21.482026-01-13
3 month-8.15%USD 23.562025-11-14
Year to date+0.42%USD 21.552025-12-31
1 year+142.87%USD 8.912025-02-12
3 year+167.49%USD 8.092023-02-13
5 year+140.71%USD 8.992021-02-12
Since inception+27.29%USD 17.002024-04-15

AVDL News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

AVDL Financials

Key Financial Metrics (TTM)

Gross Margin

95.49%

Operating Margin

3.95%

Net Income Margin

2.41%

Return on Equity

5.44%

Return on Capital

-56.12%

Return on Assets

2.39%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$234.76M

Operating Income

$4.52M

EBITDA

$10.13M

Operating Cash Flow

$35.60M

Capital Expenditure

-$191.76K

Free Cash Flow

$35.41M

Cash & ST Invst.

$91.58M

Total Debt

$37.38M

Avadel Pharmaceuticals Plc Performance Analysis

Avadel Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
20232023-12-31USD 27,963,000N/A
20242024-12-31USD 169,117,000504.8%
Avadel Pharmaceuticals Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-310.8%
Q12025-03-314.2%
Q22025-06-3029.7%
Q32025-09-3013.7%
Avadel Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -1.32N/A
20222022-12-31USD -2.2973.2%
20232023-12-31USD -2.00-12.6%
20242024-12-31USD -0.51-74.3%
Avadel Pharmaceuticals Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-12-31-66.7%
Q12025-03-31N/A
Q22025-06-30300.0%
Q32025-09-30-99.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$77.47M

+54.9%

Gross Profit

$80.47M

+83.4%

Gross Margin

1.04%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

188

N/A

Net Income

$20.00K

+100.8%

EBITDA

$3.58M

+171.9%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$91.58M

+39.2%

Total Debt

$37.38M

+1825.7%

Accounts Receivable

$42.44M

+14.4%

Inventory

$23.91M

+48.5%

Long Term Debt

$36.64M

+2913.0%

Short Term Debt

$740.00K

+2.1%

Return on Assets

2.39%

N/A

Return on Invested Capital

5.71%

N/A

Free Cash Flow

$23.25M

+437.4%

Operating Cash Flow

$23.26M

+437.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PAHCPhibro Animal Health Corporation
$34.52+2.31%
BGMBGM Group Ltd.
$0.29-6.11%
ANIPANI Pharmaceuticals, Inc.
$81.92+1.36%
ALVOAlvotech
$3.37-0.30%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$15.60-0.00%
ATAIAtaiBeckley
$7.15+0.33%
NOKNokia
$10.38-0.08%
ONDSOndas
$6.65-0.06%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.